Nettis E, Di Leo E, Pastore A, Distaso M, Zaza I, Vacca M, Macchia L, Vacca A
Department of Allergy and Clinical Immunology, University of Bari Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy. Phone: +39 080 5592 821 Fax: +39 080 5593 576 E-mail:
Section of Allergology and Clinical Immunology, Unit of Internal Medicine, "F. Miulli" Hospital, Acquaviva delle Fonti, Bari, Italy.
Eur Ann Allergy Clin Immunol. 2016 Sep;48(5):182-7.
Background. In chronic spontaneous urticaria (CSU) first-line therapy with an antihistamine-based regimen may not achieve satisfactory control in patients. Thus, a continuing need exists for effective and safe treatments for refractory CSU. Aim. To evaluate the clinical efficacy and safety of an intake of a combination of 2 probiotics (Lactobacillus salivarius LS01 and Bifidobacterium breve BR03) in patients with CSU who remain symptomatic despite concomitant H1-antihistamine therapy. Methods. This report analyzes the effects of therapy with two probiotic strains on the clinical progress of 52 unselected patients with difficulty to treat CSU underwent to medical examination in two Italian specialist urticaria Clinics between September 2013 and September 2014. A mixture of Lactobacillus LS01 and Bifidobacterium BR03 were administered in each patient twice daily for 8 weeks. To evaluate patients' improvement with probiotics, urticaria activity score over 7 days (UAS7) was used at baseline and at week 8 in addition to a 5-question urticaria quality of life questionnaire. Results. Fifty-two patients with CSU were included in this study (10 male and 42 female, age range 19-72 years). Mean disease duration was 1.5 years. Fourteen patients discontinued treatment, so evaluable population consisted of 38 patients. Nine of the 38 patients experienced mild clinical improvement during probiotic treatment (23.7%); one patient reported significant clinical improvement (2.6%) and one patient had complete remission of urticaria (2.6%). Twenty-seven patients did not have improvement in symptoms (71.1%). No side effects during the course of therapy were reported. Conclusions. A combination of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03 administered twice daily for 8 weeks might reduce the symptoms scores and improve quality of life scores in a part of patients with CSU who remained symptomatic despite treatment with H1 antihistamine mostly in subjects with allergic rhinitis.
背景。在慢性自发性荨麻疹(CSU)中,基于抗组胺药的一线治疗方案可能无法使患者获得满意的控制效果。因此,对于难治性CSU,一直需要有效且安全的治疗方法。目的。评估在接受H1抗组胺药治疗后仍有症状的CSU患者中,摄入两种益生菌(唾液乳杆菌LS01和短双歧杆菌BR03)组合的临床疗效和安全性。方法。本报告分析了2013年9月至2014年9月期间,在意大利两家专业荨麻疹诊所接受医学检查的52例未经选择的难治性CSU患者,使用两种益生菌菌株治疗对其临床进展的影响。每位患者每日服用两次唾液乳杆菌LS01和短双歧杆菌BR03的混合物,持续8周。为了评估益生菌对患者的改善情况,除了一份包含5个问题的荨麻疹生活质量问卷外,在基线和第8周时使用7天荨麻疹活动评分(UAS7)。结果。本研究纳入了52例CSU患者(10例男性和42例女性,年龄范围19 - 72岁)。平均病程为1.5年。14例患者停止治疗,因此可评估人群包括38例患者。38例患者中有9例在益生菌治疗期间出现轻度临床改善(23.7%);1例患者报告有显著临床改善(2.6%),1例患者荨麻疹完全缓解(2.6%)。27例患者症状未改善(71.1%)。治疗过程中未报告有副作用。结论。对于部分尽管使用H1抗组胺药治疗仍有症状的CSU患者,尤其是患有过敏性鼻炎的患者,每日服用两次唾液乳杆菌LS01和短双歧杆菌BR03的组合,持续8周,可能会降低症状评分并改善生活质量评分。